^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AMXI-5001
i
Other names: AMXI-5001, AMXI 5001, AMXI5001
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
AtlasMedx
Drug class:
PARP inhibitor, Tubulin polymerization inhibitor
Related drugs:
8ms
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies (clinicaltrials.gov)
P1/2, N=122, Active, not recruiting, AtlasMedx, Incorporated | Recruiting --> Active, not recruiting
Enrollment closed • Metastases
|
AMXI-5001
over1year
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies (clinicaltrials.gov)
P1/2, N=122, Recruiting, AtlasMedx, Incorporated | N=80 --> 122 | Trial completion date: Jan 2023 --> Jan 2025 | Trial primary completion date: Jan 2023 --> Jan 2025
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
AMXI-5001
4years
AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers. (PubMed, Am J Cancer Res)
AMXI-5001 demonstrates comparable IC50 inhibition against PARP and microtubule polymerization as clinical PARP inhibitors (Olaparib, Rucaparib, Niraparib, and Talazoparib) and the potent polymerization inhibitor (Vinblastine), respectively. AMXI-5001 resulted in superior anti-tumor effects compared to either single agent (PARP or microtubule) inhibitor or combination with both agents. AMXI-5001 will enter clinical trial testing soon and represents a promising, novel first in class dual PARP1/2 and microtubule polymerization inhibitor that delivers continuous and synchronous one-two punch cancer therapy with one molecule.
Journal • BRCA Biomarker • PARP Biomarker
|
BRCA (Breast cancer early onset) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
|
BRCA mutation
|
Lynparza (olaparib) • Talzenna (talazoparib) • Zejula (niraparib) • Rubraca (rucaparib) • vinblastine • AMXI-5001
Share via
